NASDAQ:GYRE Gyre Therapeutics (GYRE) Stock Price, News & Analysis $4.34 -0.22 (-4.82%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$4.42 +0.08 (+1.73%) As of 11/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Gyre Therapeutics Stock (NASDAQ:GYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gyre Therapeutics alerts:Sign Up Key Stats Today's Range$4.34▼$4.7250-Day Range$4.01▼$7.5552-Week Range$3.97▼$9.14Volume466,619 shsAverage Volume226,525 shsMarket Capitalization$500.49 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure. The company adopted the Gyre Therapeutics name in 2023, following its predecessor Catalyst Biosciences’ acquisition of a majority stake in Gyre Pharmaceuticals. This brought together U.S.-based drug development activities and established pharmaceutical operations in China.AI Generated. May Contain Errors. Read More Gyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks12th Percentile Overall ScoreGYRE MarketRank™: 0.58904109589 of 5 starsGyre Therapeutics scored higher than 12% of companies evaluated by MarketBeat, and ranked 1635th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingReduce Consensus RatingGyre Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageGyre Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Gyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Gyre Therapeutics are expected to decrease in the coming year, from ($0.34) to ($0.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gyre Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gyre Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGyre Therapeutics has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.22% of the float of Gyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverGyre Therapeutics has a short interest ratio ("days to cover") of 14.22, which indicates bearish sentiment.Change versus previous monthShort interest in Gyre Therapeutics has recently increased by 16.26%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGyre Therapeutics does not currently pay a dividend.Dividend GrowthGyre Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment0.58 News SentimentGyre Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Gyre Therapeutics this week, compared to 1 article on an average week.Search Interest2 people have searched for GYRE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Gyre Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Gyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.50% of the stock of Gyre Therapeutics is held by insiders.Percentage Held by Institutions23.99% of the stock of Gyre Therapeutics is held by institutions.Read more about Gyre Therapeutics' insider trading history. Receive GYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GYRE Stock News HeadlinesGyre Therapeutics (NASDAQ:GYRE) Shares Climb 14.5% After Strong EarningsNovember 8, 2026 | americanbankingnews.comGyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars. | Behind the Markets (Ad)Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesNovember 5, 2026 | globenewswire.comGyre Therapeutics, Inc. enters into new employment agreements on October 16, 2026October 22, 2026 | msn.comGyre Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)August 12, 2026 | theglobeandmail.comGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateAugust 7, 2026 | globenewswire.comSee More Headlines GYRE Stock Analysis - Frequently Asked Questions How have GYRE shares performed this year? Gyre Therapeutics' stock was trading at $7.06 at the start of the year. Since then, GYRE stock has decreased by 38.5% and is now trading at $4.34. How were Gyre Therapeutics' earnings last quarter? Gyre Therapeutics, Inc. (NASDAQ:GYRE) announced its earnings results on Thursday, November, 5th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.19. The business earned $32.93 million during the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative trailing twelve-month return on equity of 7.39% and a negative net margin of 14.80%. Who are Gyre Therapeutics' major shareholders? Top institutional investors of Gyre Therapeutics include State Street Corp (0.21%), SBI Securities Co. Ltd. (0.15%) and Goldman Sachs Group Inc. (0.05%). Insiders that own company stock include Songjiang Ma, Ying Luo, Weiguo Ye and Nassim Usman. View institutional ownership trends. How do I buy shares of Gyre Therapeutics? Shares of GYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (19m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GYRE's financial health is in the Red zone, according to TradeSmith. GYRE has been in this zone for over 19 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GYRE Previous SymbolNASDAQ:GYRE CIK1124105 Webwww.gyretx.com Phone(619) 949-3681Fax336-480-2107Employees618Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.03 million Net Margins-14.80% Pretax Margin-13.60% Return on Equity-7.39% Return on Assets-5.74% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio3.89 Sales & Book Value Annual Sales$116.59 million Price / Sales4.29 Cash Flow$0.21 per share Price / Cash Flow20.52 Book Value$1.25 per share Price / Book3.47Miscellaneous Outstanding Shares115,320,000Free Float104,366,000Market Cap$500.49 million OptionableOptionable Beta2.14 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GYRE) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour secret “Black Friday” link for tradersMarkham Trading's complete Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 f...TradeWins | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.